Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer. Awad MM, Forde PM, Girard N, Spicer J, et al. J Clin Oncol 2025 Jan 8:JCO2402239. doi: 10.1200/JCO-24-02239.

Read + Share

Amedeo Smart

Independent Medical Education

Awad MM, Forde PM, Girard N, Spicer J, et al. Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer. J Clin Oncol 2025 Jan 8:JCO2402239. doi: 10.1200/JCO-24-02239.
PMID: 39778121